| Clinical outcomes of cyclin-dependent kinase 4–6 (CDK 4–6) inhibitors in patients with male breast cancer: A multicenter study HÇ Yıldırım, E Mutlu, E Chalabiyev, M Özen, M Keskinkılıç, S Ön, A Çelebi, ... The Breast 66, 85-88, 2022 | 14 | 2022 |
| Advances in the early detection of hepatobiliary cancers HÇ Yıldırım, G Kavgaci, E Chalabiyev, O Dizdar Cancers 15 (15), 3880, 2023 | 10 | 2023 |
| Immunogenicity of two doses of inactive COVID‐19 vaccine and third booster dose mRNA vaccine in patients with cancer receiving active systemic therapy DC Guven, FGG Incesu, HC Yildirim, E Erul, E Chalabiyev, BY Aktas, ... International Journal of Cancer 152 (4), 679-685, 2023 | 7 | 2023 |
| KELIM score predicts outcome in patients with platinum-resistant/refractory recurrent ovarian cancer F Kus, DC Guven, HC Yildirim, E Chalabiyev, A Akyildiz, OD Tatar, ... Biomarkers in Medicine 17 (7), 379-389, 2023 | 5 | 2023 |
| Efficacy of first-line CDK 4-6 inhibitors in premenopausal patients with metastatic breast cancer and the effect of dose reduction due to treatment-related neutropenia on … HC Yildirim, C Kapar, B Koksal, M Seyyar, PC Sanci, M Guliyev, P Perkin, ... Journal of Chemotherapy 37 (1), 69-75, 2025 | 4 | 2025 |
| The efficacy of palbociclib and ribociclib in the first-line treatment of metastatic hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer … HÇ Yıldırım, Y Kutlu, E Mutlu, MB Aykan, M Korkmaz, S Yalçın, T Şakalar, ... International Journal of Clinical Oncology 29 (3), 258-265, 2024 | 3 | 2024 |
| The incidence and risk factors for acute kidney injury in patients treated with immune checkpoint inhibitors DC Guven, DA Ozbek, TK Sahin, G Kavgaci, MS Aksun, E Erul, ... Anti-Cancer Drugs 34 (6), 783-790, 2023 | 3 | 2023 |
| Do statins enhance the antitumor effect of trastuzumab emtansine (T-DM1)?: Real-life cohort A Akyildiz, DC Guven, HC Yildirim, R Ismayilov, F Yilmaz, OD Tatar, ... Medicine 102 (18), e33677, 2023 | 3 | 2023 |
| Emerging treatment strategies in hepatobiliary cancer DC Guven, HC Yildirim, E Chalabiyev, F Kus, F Yilmaz, S Yasar, ... Expert Review of Anticancer Therapy 23 (3), 243-256, 2023 | 2 | 2023 |
| Prognostic factors associated with locally advanced gastric cancer in patients treated with adjuvant chemotherapy H YILDIRIM, D Güven, E Chalabiyev, H Taban, F YILMAZ, S YAŞAR, ... Journal of Oncological Science 8 (3), 2022 | 2 | 2022 |
| Sirolimus experience in adult patients with vascular malformations A Akyildiz, R Ismayilov, DC Guven, HC Yildirim, OD Tatar, F Kus, ... Vascular, 17085381241241853, 2024 | 1 | 2024 |
| Bi-weekly irinotecan is an effective and convenient regimen in the treatment of relapsed or refractory small cell lung cancer F Yılmaz, S Yaşar, ÖD Tatar, HÇ Yıldırım, DC Güven, A Akyıldız, ... BMC cancer 24 (1), 1218, 2024 | | 2024 |
| Comparison of the efficacy of sunitinib and pazopanib in patients with advanced non-clear renal cell carcinoma HC Yildirim, E Bayram, E Chalabiyev, N Majidova, T Avci, HG Güzel, ... Journal of Chemotherapy, 1-12, 2024 | | 2024 |
| The Use of Herbal Medicine and Dietary Supplements in Cancer Patients Receiving Immune Checkpoint Inhibitors: A Multicenter Cross-Sectional Study F Kus, D Can Guven, HC Yildirim, B Akagunduz, S Karakaya, O Sutcuoglu, ... Integrative cancer therapies 23, 15347354241280273, 2024 | | 2024 |
| 1502P Sexual dysfunction and quality of life in rectal cancer F Kus, HC Yildirim, DC Guven, E Chalabiyev, F Sirvan, O Dizdar, S Yalcin Annals of Oncology 35, S920-S921, 2024 | | 2024 |
| The impact of human epidermal growth factor receptor-2 (low) status on the efficacy of first line cyclin-dependent kinase 4/6 inhibitors in advanced breast cancer HC Yildirim, M Buyukkor, G Kavgaci, BŞ Celik, KB Yucel, B Dursun, ... Medicine 103 (30), e38828, 2024 | | 2024 |
| KELIM score predicts outcome in patients with platinum-resistant/refractory recurrent ovarian cancer F Kus, DC Guven, HC Yildirim, E Chalabiyev, A Akyildiz, OD Tatar, ... Biomarkers in Medicine 18 (10-12), 511-511, 2024 | | 2024 |
| Adjuvant denosumab treatment in patients with resectable high-risk giant cell tumor of bone A Akyıldız, R Ismayılov, D Güven, E Chalabiyev, N Abdurrahimli, S Aksoy Anatolian Current Medical Journal 6 (3), 225-228, 2024 | | 2024 |
| Immunotherapy for Ovarian/Fallopian Tube Cancer Patients E CHALABIYEV, Z ARIK Turkiye Klinikleri Medical Oncology-Special Topics 17 (1), 110-112, 2024 | | 2024 |
| 429P The impact of HER2 status on the efficacy of CDK 4/6 inhibitors: A multicenter study HC Yildirim, M Büyükkör, B Sahin, KB Yucel, B Dursun, E Chalabiyev, ... Annals of Oncology 34, S362, 2023 | | 2023 |
Deniz Can GuvenHacettepe University Internal Medicine確認したメール アドレス: hacettepe.edu.tr
